No Shaw's clients took underwritten stock from the Rights Issue, it was all accounted for in the Substantial Shareholder notices.This has been posted many times.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%